Citation: | Guideline on immunosuppressive therapy of recipients with renal transplantation in China(2016 edition)[J]. ORGAN TRANSPLANTATION, 2016, 7(5): 327-331. doi: 10.3969/j.issn.1674-7445.2016.05.001 |
[1] |
Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey [J]. Lancet, 2012, 379 (9818): 815-822. doi: 10.1016/S0140-6736(12)60033-6
|
[2] |
王汀, 江金财, 俞志勇, 等.2013中国器官移植大会会议纪要[J/CD].中华移植杂志(电子版), 2014, 8(1): 42-6. http://www.doc88.com/p-9691853876929.html
Wang T, Jiang JC, Yu ZY, et al. Organ transplantation conference in 2013 [J/CD]. Chin J Transplant (Electr Edit), 2014, 8(1): 42-6. http://www.doc88.com/p-9691853876929.html
|
[3] |
Hammond EB, Taber DJ, Weimert NA, et al. Efficacy of induction therapy on acute rejection and graft outcomes in African American kidney transplantation [J]. Clin Transplant, 2010, 24 (1): 40-7. doi: 10.1111/ctr.2010.24.issue-1
|
[4] |
Ji SM, Li LS, Cheng Z, et al. A single-dose daclizumab induction protocol in renal allograft recipients: a Chinese single center experience [J]. Transplant Proc, 2007, 39 (5): 1396-1401. doi: 10.1016/j.transproceed.2006.11.016
|
[5] |
Kidney Disease: Improving Global Outcomes(KDIGO)Transplant Work Group.KDIGO clinical practice guideline for the care of kidney transplant recipients [J]. Am J Transplant, 2009, 9 (Suppl3): S1-S155. http://www.kdigo.org/clinical_practice_guidelines/pdf/KITxpGL_SupplementaryTables.pdf
|
[6] |
Ekberg H, van Gelder T, Kaplan B, et al.Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation [J]. Transplantation, 2011, 92 (1): 82-87. doi: 10.1097/TP.0b013e31821fad06
|
[7] |
Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation[ J]. N Engl J Med, 2007, 357 (25): 2562-2575. doi: 10.1056/NEJMoa067411
|
[8] |
Ekbal NJ, Holt DW, Macphee IA. Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients [J]. Pharmacogenomics, 2008, 9 (5): 585-596. doi: 10.2217/14622416.9.5.585
|
[9] |
Utecht KN, Hiles JJ, Kolear J. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors [J]. Am J Health Syst Pharm, 2006, 63 (23): 2340-2348. doi: 10.2146/ajhp060080
|
[10] |
Lionaki S, Panagiotellis K, Iniotaki A, et al. Incidence and clinical significance of de novo donor specific antibodies after kidney transplantation [J]. Clin Dev Immunol, 2013: 849835. http://www.ncbi.nlm.nih.gov/pubmed/24348683
|
[11] |
WiebeC, GibsnIW, Blydt-HansnTD, etal. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant [J]. Am J Transplant, 2012, 12 (5): 1157-1167. doi: 10.1111/j.1600-6143.2012.04013.x
|
[12] |
Vasconcellos LM, Schachter AD, Zheng XX, et al. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts [J]. Transplantation, 1998, 66 (5): 562-566. doi: 10.1097/00007890-199809150-00002
|
[13] |
Girlanda R, Kirk AD. Frontiers in nephrology: immune tolerance to allografts in humans[ J]. J Am Soc Nephrol, 2007, 18 (8): 2242-2251. doi: 10.1681/ASN.2007020180
|
[14] |
Laftavi MR, Sharma R, Feng L, et al. Induction therapy in renal transplant recipients: a review [J]. Immunol Invest, 2014, 43 (8): 790-806. doi: 10.3109/08820139.2014.914326
|